Patient Experience Survey Of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
Authors:
- Nancy HolekampNHNancy Holekamp
- Brittany GentileBGBrittany Gentile
- Audrey Giocanti-AuréganAGAudrey Giocanti-Aurégan
- Alfredo Garcia-LayanaAGAlfredo Garcia-Layana
- Tunde PetoTPTunde Peto
- Francesco ViolaFVFrancesco Viola
- Peter J. KertesPKPeter J. Kertes
- Mirela MirtMMMirela Mirt
- Aachal KotechaAKAachal Kotecha
- Jérémy LambertJLJérémy Lambert
- Hannah B. LewisHLHannah B. Lewis
- Gloria C. ChiGCGloria C. Chi
Open Access
- 29 April 2024
- journal article
- research article
- Published by S. Karger AG in Ophthalmic Research
- Vol. 67 (1) , 1
Abstract
Introduction: Understanding patient perspectives of treatment may improve adherence and outcomes. This study explored real-world patient experiences with anti-vascular endothelial growth factor (anti-VEGF) treatment for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). Methods: This multinational, non-interventional, quantitative, cross-sectional, observational survey assessed treatment barriers/burden, patient-reported visual functioning, and treatment satisfaction in DME and nAMD patients in the United States, United Kingdom, Canada, France, Italy, and Spain. Treatment patterns and visual outcomes were extracted from medical charts. Regression models evaluated relationships between adherence, total missed visits, number of anti-VEGF injections and clinical and patient-reported outcomes for visual functioning. Association between treatment satisfaction and aspects of burden were assessed. Results: The survey was completed by 183 DME and 391 nAMD patients. Patients had moderately high vision-related functioning (25-item National Eye Institute Visual Functioning Questionnaire score: mean=74.8) and were satisfied with their current treatment (mean total score: Macular Disease Treatment Satisfaction Questionnaire=59.2; Retinopathy Treatment Satisfaction Questionnaire=61.3). Treatment satisfaction scores were worse with higher time-related impacts of treatment (nAMD/DME), higher impacts on finances and daily life (nAMD), negative impact on employment and lower expectations for treatment effectiveness (DME). Most patients reported ≥1 barrier (66.1% DME, 49.2% nAMD patients) related to treatment (35.0%), clinic (32.6%), and COVID-19 (21.1%). Moreover, 44.9% of patients reported some impairment in activities of daily living. Work absenteeism was observed among >60% of working patients. Nearly one-quarter (24.2%) of patients needed ≥1 day to recover from intravitreal injections; most reported ≥30 minutes of travel time (73.7%) and clinic wait time (54.2%). In unadjusted univariable analyses, treatment adherence (vs non adherence) was related to higher most recent visual acuity (β = 8.98 letters; CI, 1.34–16.62) and lower odds of visual acuity below driving vision (≤ 69 letters) (OR = 0.50; CI, 0.25–1.00) . Conclusion: More durable treatments with reduced frequency of injections/visits may reduce treatment burden and improve patient satisfaction, which may enhance adherence and visual outcomes.Keywords
This publication has 23 references indexed in Scilit:
- nAMD: optimization of patient care and patient-oriented information with the help of an internet-based surveyGraefe's Archive for Clinical and Experimental Ophthalmology, 2022
- Impact of the COVID-19 pandemic’s first wave on the care and treatment situation of intravitreal injections in a German metropolitan regionGraefe's Archive for Clinical and Experimental Ophthalmology, 2022
- Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular DegenerationJAMA Ophthalmology, 2020
- Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye serviceEye, 2019
- COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICERetina, 2018
- Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging ChallengesAdvances in Therapy, 2017
- Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysisThe Lancet Global Health, 2014
- NOVEL METHOD FOR ANALYZING SNELLEN VISUAL ACUITY MEASUREMENTSRetina, 2010
- Psychometric development of the Retinopathy Treatment Satisfaction Questionnaire (RetTSQ)Psychology, Health & Medicine, 2009
- Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Quality-of-life findingsSST report no. 12Ophthalmology, 2004